Lenalidomide has been extensively evaluated across numerous clinical trials spanning Early Phase 1 through Phase 4, focusing primarily on hematologic malignancies—including multiple myeloma, smoldering multiple myeloma, chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma—alongside exploratory studies in neurodegenerative and inflammatory disorders. Sponsored by government institutes, academic medical centers, and pharmaceutical companies, these trials encompass various recruitment statuses, including completed, active, recruiting, terminated, and withdrawn. Together, these studies underscore its broad investigation in diverse therapeutic strategies and combination regimens.
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT07428369 | WITHDRAWN | Multiple Myeloma (MM) |
Regeneron Pharmaceuticals |
2026-06-05 | PHASE2; PHASE3 |
| NCT06932562 | RECRUITING | Multiple Myeloma |
European Myeloma Network B.V. |
2025-12-23 | PHASE3 |
| NCT04446962 | ACTIVE_NOT_RECRUITING | Lymphoma, Large B-Cell, Diffuse; Central Nervous System Neoplasms, Primary |
Institut Curie |
2020-10-30 | PHASE1; PHASE2 |
| NCT05259839 | ACTIVE_NOT_RECRUITING | Relapsed/Refractory Multiple Myeloma |
AbbVie |
2022-10-20 | PHASE1 |
| NCT05257083 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Stichting European Myeloma Network |
2023-10-10 | PHASE3 |
| NCT05145400 | RECRUITING | Multiple Myeloma; Cancer |
UNC Lineberger Comprehensive Cancer Center |
2022-02-18 | PHASE2 |
| NCT06974786 | RECRUITING | Multiple Myeloma, Newly Diagnosed; Multiple Myeloma (MM) |
SCRI Development Innovations, LLC |
2025-08-08 | PHASE2 |
| NCT05283720 | ACTIVE_NOT_RECRUITING | Non-Hodgkin Lymphoma |
Genmab |
2022-06-14 | PHASE2 |
| NCT06182774 | RECRUITING | Multiple Myeloma |
Canadian Cancer Trials Group |
2024-04-10 | PHASE3 |
| NCT07285239 | RECRUITING | Multiple Myeloma |
PrECOG, LLC. |
2026-09 | PHASE3 |
| NCT05561387 | RECRUITING | Plasma Cell Myeloma |
SWOG Cancer Research Network |
2023-10-12 | PHASE3 |
| NCT06679101 | RECRUITING | Multiple Myeloma; Newly Diagnosed Multiple Myeloma |
GlaxoSmithKline |
2024-12-16 | PHASE3 |
| NCT07719543 | NOT_YET_RECRUITING | Immunoglobulin G4-Related Disease |
Chinese PLA General Hospital |
2026-08-01 | PHASE3 |
| NCT07247097 | NOT_YET_RECRUITING | Multiple Myeloma; Newly Diagnosed Multiple Myeloma; Transplant Ineligible; Newly Diagnosed Multiple Myeloma (NDMM) |
Massachusetts General Hospital |
2026-08-01 | PHASE2 |
| NCT06931704 | NOT_YET_RECRUITING | Multiple Myeloma |
Nantes University Hospital |
2025-05-01 | PHASE2 |
| NCT06997081 | RECRUITING | Multiple Myeloma |
University of Miami |
2025-09-16 | PHASE2 |
| NCT05469893 | RECRUITING | High-risk Smoldering Multiple Myeloma; Smoldering Multiple Myeloma; Multiple Myeloma |
Irene Ghobrial, MD |
2022-08-10 | PHASE2 |
| NCT07719855 | NOT_YET_RECRUITING | Follicular Lymphoma ( FL) |
Ruijin Hospital |
2026-07 | PHASE3 |
| NCT05867030 | WITHDRAWN | Follicular Lymphoma |
Innovent Biologics (Suzhou) Co. Ltd. |
2023-07-28 | PHASE1 |
| NCT04539236 | SUSPENDED | Myelodysplastic Syndromes |
Mikkael Sekeres, MD |
2021-11-09 | PHASE1; PHASE2 |
| NCT05848765 | RECRUITING | Relapsed Follicular Lymphoma; Refractory Follicular Lymphoma |
University of Birmingham |
2023-09-04 | PHASE2 |
| NCT04669171 | RECRUITING | Follicular Lymphoma; Marginal Zone Lymphoma |
Enterome |
2021-07-05 | PHASE1; PHASE2 |
| NCT05827016 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Bristol-Myers Squibb |
2023-06-22 | PHASE3 |
| NCT06965244 | NOT_YET_RECRUITING | Cutaneous Lupus Erythematosus (CLE) |
Assistance Publique - Hôpitaux de Paris |
2025-10-01 | PHASE3 |
| NCT07764978 | RECRUITING | Newly Diagnosed Multiple Myeloma |
AstraZeneca |
2026-06-26 | PHASE3 |
| NCT06665217 | NOT_YET_RECRUITING | Diffuse Large B-Cell Lymphoma |
Navy General Hospital, Beijing |
2025-09-24 | PHASE2 |
| NCT07709884 | NOT_YET_RECRUITING | Newly Diagnosed Multiple Myeloma; T(11;14); Sotoclax; Carfilzomib |
The First Affiliated Hospital of Soochow University |
2026-07-01 | PHASE4 |
| NCT07514169 | RECRUITING | Large B-Cell Lymphoma (LBCL) |
Ruijin Hospital |
2026-03-31 | PHASE2 |
| NCT07735637 | NOT_YET_RECRUITING | Newly Diagnosed Multiple Myeloma (NDMM) |
AstraZeneca |
2026-08-25 | PHASE3 |
| NCT05695508 | RECRUITING | Multiple Myeloma |
University of Heidelberg Medical Center |
2022-12-01 | PHASE2 |
| NCT06522555 | RECRUITING | Diffuse Large B-Cell Lymphoma |
Ruijin Hospital |
2024-07-29 | PHASE3 |
| NCT05583617 | RECRUITING | Multiple Myeloma |
Hoffmann-La Roche |
2023-11-14 | PHASE1; PHASE2 |
| NCT05888493 | ACTIVE_NOT_RECRUITING | Follicular Lymphoma (FL) |
Novartis Pharmaceuticals |
2023-10-02 | PHASE3 |
| NCT07068165 | RECRUITING | IgG4 Related Disease |
Peking Union Medical College Hospital |
2025-07-07 | PHASE2; PHASE3 |
| NCT07355283 | NOT_YET_RECRUITING | Relapsed/Refractory Follicular Lymphoma |
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. |
2026-02 | PHASE3 |
| NCT05100862 | ACTIVE_NOT_RECRUITING | Relapsed/Refractory Follicular Lymphoma; Marginal Zone Lymphoma |
BeOne Medicines |
2022-03-10 | PHASE3 |
| NCT07639138 | RECRUITING | Hepatocellular Carcinoma (HCC) |
Shunda Du |
2026-06-10 | PHASE2 |
| NCT07208981 | RECRUITING | Marginal Zone Lymphoma(MZL) |
The First Affiliated Hospital with Nanjing Medical University |
2025-08-14 | PHASE2 |
| NCT05846880 | RECRUITING | Multiple Myeloma |
Amany Keruakous, MD, MS. |
2024-12-01 | EARLY_PHASE1 |
| NCT07562022 | RECRUITING | Follicular Lymphoma (FL) |
Sinocelltech Ltd. |
2026-06-09 | PHASE3 |
| NCT05243797 | RECRUITING | Multiple Myeloma |
European Myeloma Network B.V. |
2022-09-08 | PHASE3 |
| NCT07045909 | RECRUITING | De Novo Multiple Myeloma; Anitocabtagene Autoleucel |
PETHEMA Foundation |
2025-06-30 | PHASE2 |
| NCT05137054 | RECRUITING | Multiple Myeloma |
Regeneron Pharmaceuticals |
2022-08-17 | PHASE1 |
| NCT06508658 | ACTIVE_NOT_RECRUITING | Diffuse Large B-Cell Lymphoma |
Genmab |
2024-08-13 | PHASE3 |
| NCT06744894 | NOT_YET_RECRUITING | Multiple Myeloma |
Navy General Hospital, Beijing |
2025-01-01 | PHASE2 |
| NCT06651853 | RECRUITING | Diffuse Large B-cell Lymphoma; Relapsed and Refractory |
The First Affiliated Hospital of Xiamen University |
2024-10-21 | PHASE2 |
| NCT04775550 | ACTIVE_NOT_RECRUITING | High-risk Smoldering Multiple Myeloma; Multiple Myeloma |
Omar Nadeem, MD |
2021-03-08 | PHASE2 |
| NCT06742138 | NOT_YET_RECRUITING | Multiple Myeloma |
Qilu Pharmaceutical Co., Ltd. |
2025-01 | PHASE3 |
| NCT06409702 | RECRUITING | Newly Diagnosed; High Risk; MRD; Multiple Myeloma |
The First Affiliated Hospital of Soochow University |
2024-06-12 | PHASE4 |
| NCT07018050 | RECRUITING | Relapsed or Refractory Multiple Myeloma |
Qilu Pharmaceutical Co., Ltd. |
2025-09-12 | PHASE2 |
| NCT02659293 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
University of Chicago |
2016-04-26 | PHASE3 |
| NCT07789522 | NOT_YET_RECRUITING | Multiple Myeloma (MM) |
Institute of Hematology & Blood Diseases Hospital, China |
2026-10-01 | PHASE2 |
| NCT05683171 | ACTIVE_NOT_RECRUITING | Lymphoma |
M.D. Anderson Cancer Center |
2023-05-19 | PHASE1; PHASE2 |
| NCT04542824 | ACTIVE_NOT_RECRUITING | Diffuse Large B Cell Lymphoma; High-grade B-cell Lymphoma; Primary Mediastinal Large B Cell Lymphoma; Follicular Lymphoma; Marginal Zone Lymphoma; Small Lymphocytic Lymphoma |
Genmab |
2020-08-20 | PHASE1; PHASE2 |
| NCT04792502 | RECRUITING | Follicular Lymphoma; Marginal Zone Lymphoma; B-cell Lymphoma |
Brown University |
2022-07-14 | PHASE2 |
| NCT06084936 | RECRUITING | Lymphoma |
Hoffmann-La Roche |
2023-10-22 | PHASE3 |
| NCT05317416 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Pfizer |
2022-03-25 | PHASE3 |
| NCT05665140 | RECRUITING | Newly Diagnosed Multiple Myeloma |
University Hopsital Schleswig Holstein Campus Lübeck |
2023-02-03 | PHASE2; PHASE3 |
| NCT07261163 | RECRUITING | Mantle Cell Lymphoma |
Institute of Hematology & Blood Diseases Hospital, China |
2025-12-20 | PHASE2 |
| NCT06895512 | NOT_YET_RECRUITING | Newly Diagnosed Multiple Myeloma |
Shanghai Henlius Biotech |
2025-04 | PHASE3 |
| NCT05279300 | SUSPENDED | Advanced Solid Tumor; Advanced Lymphoma |
CStone Pharmaceuticals |
2022-03-28 | PHASE1 |
| NCT04301076 | RECRUITING | Acute Adult T-Cell Leukemia/Lymphoma; Adult T-Cell Leukemia/Lymphoma; Chronic Adult T-Cell Leukemia/Lymphoma; HTLV-1 Infection |
National Cancer Institute (NCI) |
2021-08-31 | PHASE1 |
| NCT01297764 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Hackensack Meridian Health |
2011-04 | PHASE1; PHASE2 |
| NCT06348147 | WITHDRAWN | Newly Diagnosed Multiple Myeloma; Multiple Myeloma; Autologous Stem Cell Transplantation |
UNC Lineberger Comprehensive Cancer Center |
2026-07 | PHASE2 |
| NCT02420860 | ACTIVE_NOT_RECRUITING | Hematopoietic Cell Transplantation Recipient; Plasma Cell Myeloma |
M.D. Anderson Cancer Center |
2015-04-14 | PHASE2 |
| NCT07187167 | RECRUITING | Rosai-Dorfman Disease |
Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
2025-04-12 | PHASE2 |
| NCT07081022 | ACTIVE_NOT_RECRUITING | B-cell Non-Hodgkin's Lymphoma |
Shanghai Junshi Bioscience Co., Ltd. |
2025-08-17 | PHASE2 |
| NCT03319667 | ACTIVE_NOT_RECRUITING | Plasma Cell Myeloma |
Sanofi |
2017-12-07 | PHASE3 |
| NCT05558319 | RECRUITING | Newly Diagnosed Multiple Myeloma |
PETHEMA Foundation |
2022-11-10 | PHASE3 |
| NCT04133636 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Janssen Research & Development, LLC |
2019-11-07 | PHASE2 |
| NCT04224493 | ACTIVE_NOT_RECRUITING | Relapsed/Refractory Follicular Lymphoma; Follicular Lymphoma; Refractory Follicular Lymphoma |
Epizyme, Inc. |
2020-06-11 | PHASE3 |
| NCT05861050 | RECRUITING | Blastoid Variant Mantle Cell Lymphoma; Mantle Cell Lymphoma; Pleomorphic Variant Mantle Cell Lymphoma |
City of Hope Medical Center |
2023-08-10 | PHASE1; PHASE2 |
| NCT03070327 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Memorial Sloan Kettering Cancer Center |
2017-02-27 | PHASE1 |
| NCT04978584 | ACTIVE_NOT_RECRUITING | Diffuse Large B-Cell Lymphoma |
M.D. Anderson Cancer Center |
2022-03-03 | PHASE2 |
| NCT03829371 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
University of Turin, Italy |
2019-01-03 | PHASE4 |
| NCT07764861 | NOT_YET_RECRUITING | Multiple Myeloma |
Innovent Biologics (Suzhou) Co. Ltd. |
2026-08-15 | PHASE2 |
| NCT06764017 | RECRUITING | Diffuse Large B-Cell Lymphoma |
First Affiliated Hospital of Ningbo University |
2025-02-01 | PHASE2 |
| NCT05890352 | RECRUITING | Grade 3b Follicular Lymphoma; High Grade B-Cell Lymphoma; High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements; Recurrent Diffuse Large B-Cell Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Transformed Non-Hodgkin Lymphoma |
SWOG Cancer Research Network |
2023-09-26 | PHASE2 |
| NCT05950165 | ACTIVE_NOT_RECRUITING | Non-Hodgkin Lymphoma |
Cho Pharma Inc. |
2020-01-15 | PHASE1; PHASE2 |
| NCT04009109 | ACTIVE_NOT_RECRUITING | Myeloma, Multiple |
Alliance Foundation Trials, LLC. |
2020-10-21 | PHASE2 |
| NCT01562405 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Massachusetts General Hospital |
2012-05 | PHASE1 |
| NCT06517017 | RECRUITING | Multiple Myeloma; Plasma Cell Leukemia |
University of Utah |
2025-10-09 | PHASE2 |
| NCT06505369 | RECRUITING | Multiple Myeloma |
North Estonia Medical Centre |
2024-06-19 | PHASE2 |
| NCT06414148 | RECRUITING | Relapsed/Refractory Large B-cell Lymphoma |
Peter MacCallum Cancer Centre, Australia |
2024-05-14 | PHASE2 |
| NCT02886065 | ACTIVE_NOT_RECRUITING | Smoldering Multiple Myeloma |
Massachusetts General Hospital |
2017-03-07 | PHASE1 |
| NCT05690984 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Medical College of Wisconsin |
2023-06-26 | PHASE2 |
| NCT06762431 | RECRUITING | Chronic Lymphocytic Leukaemia (CLL); Small Lymphocytic Lymphoma (SLL) |
Vitebsk Regional Clinical Cancer Centre |
2024-05-14 | PHASE1; PHASE2 |
| NCT07090954 | NOT_YET_RECRUITING | Multiple Myeloma |
Genrix (Shanghai) Biopharmaceutical Co., Ltd. |
2025-08-31 | PHASE1; PHASE2 |
| NCT04635189 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
University of Rochester |
2021-07-27 | PHASE2 |
| NCT03836014 | ACTIVE_NOT_RECRUITING | Multiple Myeloma in Relapse |
Assistance Publique - Hôpitaux de Paris |
2019-07-25 | PHASE3 |
| NCT06737250 | RECRUITING | Primary CNS Lymphoma (PCNSL) |
NOBO Medicine |
2024-11-25 | PHASE2 |
| NCT05660967 | TERMINATED | Diffuse Large B-Cell Lymphoma |
Genmab |
2023-03-06 | PHASE2 |
| NCT05351346 | UNKNOWN | Diffuse Large B Cell Lymphoma |
Ruijin Hospital |
2022-06-01 | PHASE3 |
| NCT06454968 | RECRUITING | Marginal Zone Lymphoma |
Peking Union Medical College Hospital |
2024-06-20 | PHASE2 |
| NCT03697356 | UNKNOWN | Waldenström's Macroglobulinemia |
Kosin University Gospel Hospital |
2019-03-06 | PHASE2 |
| NCT05846750 | RECRUITING | Marginal Zone Lymphoma |
Institute of Hematology & Blood Diseases Hospital, China |
2022-11-01 | PHASE2 |
| NCT02544308 | ACTIVE_NOT_RECRUITING | Plasmacytoma |
University College, London |
2017-03-10 | PHASE3 |
| NCT05572229 | RECRUITING | Multiple Myeloma |
University Hospital, Lille |
2023-12-21 | PHASE2 |
| NCT05429268 | ACTIVE_NOT_RECRUITING | Large B-Cell Lymphoma; Diffuse Large B-Cell Lymphoma |
Incyte Corporation |
2022-12-23 | PHASE3 |
| NCT05849610 | ACTIVE_NOT_RECRUITING | High-Risk de Novo Multiple Myeloma |
PETHEMA Foundation |
2023-09-21 | PHASE2 |
| NCT04786028 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Canadian Myeloma Research Group |
2021-12-08 | PHASE2 |
| NCT06177028 | NOT_YET_RECRUITING | Cognitive Impairment, Mild; Cognitive Dysfunction; Amyloid Plaque; Neurodegenerative Disease, Hereditary; Inflammation, Brain |
St. Joseph's Hospital and Medical Center, Phoenix |
2025-06-01 | PHASE2 |
| NCT04096066 | ACTIVE_NOT_RECRUITING | Multiple Myeloma; New Diagnosis Tumor |
Fondazione EMN Italy Onlus |
2019-07-01 | PHASE3 |
| NCT03269669 | ACTIVE_NOT_RECRUITING | Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma; Recurrent Follicular Lymphoma; Refractory Follicular Lymphoma |
National Cancer Institute (NCI) |
2018-01-23 | PHASE2 |
| NCT04941937 | UNKNOWN | Multiple Myeloma |
Juan Du |
2022-01-27 | PHASE2 |
| NCT03641456 | UNKNOWN | Myeloma; Newly Diagnosed; High Risk |
Sun Yat-sen University |
2020-09-25 | PHASE2 |
| NCT05179733 | UNKNOWN | Diffuse Large B-Cell Lymphoma |
Ruijin Hospital |
2022-03-02 | PHASE3 |
| NCT05572515 | ACTIVE_NOT_RECRUITING | Relapsed or Refractory Multiple Myeloma |
Janssen Research & Development, LLC |
2023-03-29 | PHASE3 |
| NCT04722146 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Janssen Research & Development, LLC |
2021-03-12 | PHASE1 |
| NCT05992597 | RECRUITING | Rituximab, Lenalidomide, Zebutinib ，Mantle Cell Lymphoma |
Zhejiang Cancer Hospital |
2022-08-01 | PHASE2 |
| NCT04737889 | RECRUITING | Primary Central Nervous System Lymphoma |
Henan Cancer Hospital |
2021-01-13 | PHASE2 |
| NCT04091126 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
GlaxoSmithKline |
2019-12-18 | PHASE1 |
| NCT04032626 | COMPLETED | Cognitive Impairment, Mild; Cognitive Dysfunction; Amyloid Plaque; Neurodegeneration; Inflammation, Brain |
St. Joseph's Hospital and Medical Center, Phoenix |
2020-07-22 | PHASE2 |
| NCT05428670 | UNKNOWN | Diffuse Large B Cell Lymphoma |
First Affiliated Hospital of Wenzhou Medical University |
2022-06-15 | PHASE2 |
| NCT02005289 | COMPLETED | Contiguous Stage II Small Lymphocytic Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Prolymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Stage I Chronic Lymphocytic Leukemia; Stage I Small Lymphocytic Lymphoma; Stage II Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage III Small Lymphocytic Lymphoma; Stage IV Chronic Lymphocytic Leukemia; Stage IV Small Lymphocytic Lymphoma |
Ohio State University Comprehensive Cancer Center |
2014-01-17 | PHASE2 |
| NCT05771883 | UNKNOWN | B-cell Non-Hodgkin's Lymphoma |
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. |
2023-05 | PHASE1; PHASE2 |
| NCT07150091 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
GlaxoSmithKline |
2022-07-19 | PHASE1; PHASE2 |
| NCT05201248 | ACTIVE_NOT_RECRUITING | B-Cell Non-Hodgkin Lymphoma |
Genmab |
2022-03-10 | PHASE1; PHASE2 |
| NCT05050097 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Janssen Research & Development, LLC |
2021-09-22 | PHASE1 |
| NCT02446457 | ACTIVE_NOT_RECRUITING | Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3a Follicular Lymphoma |
M.D. Anderson Cancer Center |
2015-07-31 | PHASE2 |
| NCT02916771 | COMPLETED | Smoldering Multiple Myeloma |
Dana-Farber Cancer Institute |
2016-10 | PHASE2 |
| NCT04288765 | WITHDRAWN | Multiple Myeloma |
Grupo Cooperativo de Hemopatías Malignas |
2020-03-01 | PHASE3 |
| NCT05265975 | TERMINATED | Diffuse Large B-cell Lymphoma; Indolent Non-Hodgkin Lymphoma |
Antengene Corporation |
2022-04-07 | PHASE1; PHASE2 |
| NCT04432714 | RECRUITING | DLBCL; Untreated; MYC Gene Rearrangement |
The First Affiliated Hospital with Nanjing Medical University |
2020-06-09 | PHASE1; PHASE2 |
| NCT05147493 | UNKNOWN | Multiple Myeloma; Renal Impairment; Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases |
Hellenic Society of Hematology |
2022-04 | PHASE2 |
| NCT03720041 | UNKNOWN | Multiple Myeloma |
University of Leeds |
2020-08-04 | PHASE3 |
| NCT06189833 | UNKNOWN | Multiple Myeloma |
Stichting European Myeloma Network |
2023-11-23 | PHASE2 |
| NCT05060627 | ACTIVE_NOT_RECRUITING | Relapsed Multiple Myeloma |
PETHEMA Foundation |
2021-12-20 | PHASE1; PHASE2 |
| NCT02911142 | ACTIVE_NOT_RECRUITING | Primary Effusion Lymphoma; B-Cell Neoplasm |
National Cancer Institute (NCI) |
2017-07-03 | PHASE1; PHASE2 |
| NCT02575144 | UNKNOWN | Multiple Myeloma |
PETHEMA Foundation |
2015-09 | PHASE3 |
| NCT03702725 | COMPLETED | Refractory Multiple Myeloma; Multiple Myeloma in Relapse; Multiple Myeloma |
Alliance Foundation Trials, LLC. |
2019-08-29 | PHASE1 |
| NCT05032820 | COMPLETED | Multiple Myeloma |
Medical College of Wisconsin |
2022-01-05 | PHASE2 |
| NCT05788289 | TERMINATED | Mantle Cell Lymphoma; MCL |
Memorial Sloan Kettering Cancer Center |
2023-03-14 | PHASE2 |
| NCT05222555 | ACTIVE_NOT_RECRUITING | Diffuse Large B Cell Lymphoma |
Incyte Corporation |
2022-07-19 | PHASE1; PHASE2 |
| NCT05797948 | UNKNOWN | Relapsed or Refractory B-cell Non-Hodgkin Lymphoma |
The First Affiliated Hospital of Soochow University |
2022-07-01 | |
| NCT01729091 | COMPLETED | Plasma Cell Leukemia; Plasma Cell Myeloma |
M.D. Anderson Cancer Center |
2013-06-10 | PHASE2 |
| NCT04113226 | COMPLETED | Chemotherapy; Diffuse Large B-Cell Lymphoma (DLBCL), Nos; Elderly |
Centre Hospitalier Universitaire, Amiens |
2021-11-09 | PHASE2 |
| NCT05211336 | ACTIVE_NOT_RECRUITING | Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS); Aggressive B-cell Lymphoma With Secondary Involvement of the CNS |
National Cancer Institute (NCI) |
2022-04-19 | PHASE1 |
| NCT01919086 | COMPLETED | Multiple Myeloma (MM) |
Memorial Sloan Kettering Cancer Center |
2013-08-06 | PHASE2 |
| NCT01996865 | COMPLETED | Lymphoma, Non-Hodgkin |
Celgene |
2014-04-01 | PHASE3 |
| NCT04140162 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
University of Michigan Rogel Cancer Center |
2020-10-05 | PHASE2 |
| NCT05497102 | UNKNOWN | Multiple Myeloma |
Samsung Medical Center |
2021-11-08 | PHASE2 |
| NCT01476787 | COMPLETED | Follicular Lymphoma |
Celgene |
2011-12-29 | PHASE3 |
| NCT03863184 | ACTIVE_NOT_RECRUITING | Mantle Cell Lymphoma |
Weill Medical College of Cornell University |
2019-10-11 | PHASE2 |
| NCT05105412 | TERMINATED | Peripheral T-cell Lymphomas (PTCL) |
National Health Research Institutes, Taiwan |
2022-06-15 | PHASE1; PHASE2 |
| NCT04436107 | COMPLETED | Relapsed/Refractory Diffuse Large B-Cell Lymphoma |
BeiGene |
2020-09-11 | PHASE1 |
| NCT03413800 | COMPLETED | Relapsed Hematologic Malignancy; Multiple Myeloma |
Ciusss de L'Est de l'Île de Montréal |
2018-02-12 | PHASE2 |
| NCT04892264 | TERMINATED | Plasma Cell Myeloma; Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma |
Mayo Clinic |
2021-06-03 | PHASE1 |
| NCT05288062 | TERMINATED | Plasma Cell Myeloma; Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma; Smoldering Plasma Cell Myeloma |
Mayo Clinic |
2022-06-15 | PHASE2 |
| NCT04680052 | ACTIVE_NOT_RECRUITING | Follicular Lymphoma; Marginal Zone Lymphoma |
Incyte Corporation |
2021-04-15 | PHASE3 |
| NCT05200312 | UNKNOWN | Non Hodgkin Lymphoma; Diffuse Large B Cell Lymphoma |
The First Affiliated Hospital with Nanjing Medical University |
2022-02-01 | PHASE2 |
| NCT03269136 | COMPLETED | Multiple Myeloma |
Pfizer |
2017-11-29 | PHASE1 |
| NCT04352205 | TERMINATED | Plasma Cell Myeloma; Renal Failure |
Emory University |
2020-05-07 | PHASE2 |
| NCT05186558 | UNKNOWN | Lymphoma, Large B-Cell, Diffuse; Neoplasms by Histologic Type |
The First Affiliated Hospital with Nanjing Medical University |
2022-05-15 | PHASE2 |
| NCT04110301 | RECRUITING | Follicular Lymphoma and Marginal Zone Lymphoma |
Beijing Mabworks Biotech Co., Ltd. |
2019-11-28 | PHASE1; PHASE2 |
| NCT05784987 | UNKNOWN | Diffuse Large B-cell Lymphoma |
The First Affiliated Hospital with Nanjing Medical University |
2023-04-15 | |
| NCT06177028 | Not yet recruiting | Cognitive Impairment Mild|Cognitive Dysfunction|Amyloid Plaque|Neurodegenerative Disease Hereditary|Inflammation Brain |
St. Joseph''s Hospital and Medical Center Phoenix|Texas Tech University |
2024-01-02 | Phase 2 |
| NCT04129710 | UNKNOWN | Recurrent/RefractoryPrimary Central Nervous System Lymphoma (PCNSL) |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2020-01-01 | PHASE2 |
| NCT04214626 | COMPLETED | Diffuse Large B Cell Lymphoma |
Henan Cancer Hospital |
2020-01-05 | PHASE2 |
| NCT04635683 | WITHDRAWN | Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Recurrent Follicular Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3a Follicular Lymphoma; Recurrent Lymphoplasmacytic Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Nodal Marginal Zone Lymphoma; Recurrent Splenic Marginal Zone Lymphoma; Recurrent Waldenstrom Macroglobulinemia; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue; Refractory Follicular Lymphoma; Refractory Grade 1 Follicular Lymphoma; Refractory Grade 2 Follicular Lymphoma; Refractory Grade 3a Follicular Lymphoma; Refractory Lymphoplasmacytic Lymphoma; Refractory Mantle Cell Lymphoma; Refractory Marginal Zone Lymphoma; Refractory Nodal Marginal Zone Lymphoma; Refractory Splenic Marginal Zone Lymphoma; Refractory Waldenstrom Macroglobulinemia |
Yazeed Sawalha |
2022-09-30 | PHASE1 |
| NCT04049864 | UNKNOWN | Relapsed Neuroblastoma |
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology |
2019-01-09 | EARLY_PHASE1 |
| NCT04922567 | RECRUITING | Peripheral T-Cell Lymphoma; Lenalidomide; CHOP |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2021-04-01 | PHASE2 |
| NCT04481815 | UNKNOWN | PCNSL |
Second Affiliated Hospital, Zhejiang University, School of Medicine |
2020-10-01 | PHASE2 |
| NCT04842487 | UNKNOWN | DLBCL |
Sun Yat-sen University |
2021-04-10 | PHASE2 |
| NCT04578600 | COMPLETED | Indolent B-Cell Non-Hodgkin Lymphoma; Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Chronic Lymphocytic Leukemia; Recurrent Mucosa-Associated Lymphoid Tissue Lymphoma; Recurrent Follicular Lymphoma; Recurrent Hairy Cell Leukemia; Recurrent Lymphoplasmacytic Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Chronic Lymphocytic Leukemia; Refractory Mucosa-Associated Lymphoid Tissue Lymphoma; Refractory Follicular Lymphoma; Refractory Hairy Cell Leukemia; Refractory Lymphoplasmacytic Lymphoma; Refractory Mantle Cell Lymphoma; Refractory Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Refractory Small Lymphocytic Lymphoma |
Joseph Tuscano |
2020-10-23 | PHASE1 |
| NCT05564052 | COMPLETED | Lymphoma, Mantle-Cell |
Janssen Research & Development, LLC |
2022-12-06 | PHASE2 |
| NCT06149286 | Recruiting | Relapsed/Refractory Follicular Lymphoma|Marginal Zone Lymphoma (MZL) |
Regeneron Pharmaceuticals |
2023-12-28 | Phase 3 |
| NCT06299553 | Recruiting | DLBCL - Diffuse Large B Cell Lymphoma |
Incyte Biosciences Italy S.r.l |
2023-12-04 | -- |
| NCT04151667 | COMPLETED | Multiple Myeloma |
H. Lee Moffitt Cancer Center and Research Institute |
2019-11-22 | PHASE2 |
| NCT01755975 | COMPLETED | Multiple Myeloma; Non-Hodgkin's Lymphoma |
Memorial Sloan Kettering Cancer Center |
2012-12 | PHASE1; PHASE2 |
| NCT03289299 | ACTIVE_NOT_RECRUITING | Smoldering Multiple Myeloma |
International Myeloma Foundation |
2018-05-25 | PHASE2 |
| NCT02180711 | ACTIVE_NOT_RECRUITING | Non Hodgkin Lymphoma |
Acerta Pharma BV |
2014-12-29 | PHASE1; PHASE2 |
| NCT02532257 | COMPLETED | Ann Arbor Stage II Follicular Lymphoma; Ann Arbor Stage II Marginal Zone Lymphoma; Ann Arbor Stage III Follicular Lymphoma; Ann Arbor Stage III Marginal Zone Lymphoma; Ann Arbor Stage IV Follicular Lymphoma; Ann Arbor Stage IV Marginal Zone Lymphoma; CD20 Positive; Grade 1 Follicular Lymphoma; Grade 2 Follicular Lymphoma; Grade 3a Follicular Lymphoma |
M.D. Anderson Cancer Center |
2016-04-11 | PHASE2 |
| NCT03710603 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Stichting European Myeloma Network |
2018-12-14 | PHASE3 |
| NCT05488327 | UNKNOWN | Dermatomyositis |
Jiangxi Provincial People's Hopital |
2022-08-01 | |
| NCT00848328 | TERMINATED | Lymphoma |
University of California, Davis |
2008-08-25 | PHASE2 |
| NCT04113018 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Wake Forest University Health Sciences |
2020-01-10 | PHASE2 |
| NCT01749969 | COMPLETED | Plasma Cell Myeloma |
Sanofi |
2013-02-06 | PHASE1 |
| NCT04796857 | UNKNOWN | Non-GCB/ABC Diffuse Large B-Cell Lymphoma; High-grade B-cell Lymphoma; Follicular Lymphoma Grade IIIb; Transformed Lymphoma; EBV-Positive DLBCL, Nos; ALK-Positive Anaplastic Large Cell Lymphoma |
Huiqiang Huang |
2021-03-31 | PHASE1; PHASE2 |
| NCT04842318 | UNKNOWN | Follicular Lymphoma |
Ruijin Hospital |
2021-03-01 | PHASE4 |
| NCT03544281 | COMPLETED | Multiple Myeloma |
GlaxoSmithKline |
2018-09-20 | PHASE1; PHASE2 |
| NCT04818372 | UNKNOWN | Multiple Myeloma; Lymphoma |
Keymed Biosciences Co.Ltd |
2021-04-26 | PHASE1 |
| NCT04432402 | UNKNOWN | Diffuse Large B Cell Lymphoma |
The First Affiliated Hospital with Nanjing Medical University |
2020-06-14 | |
| NCT04604028 | UNKNOWN | Antibiotics-unresponsive MALT Lymphoma; Relapsed MALT Type Extranodal Marginal Zone B-Cell Lymphoma; Refractory Extranodal Marginal Zone B-Cell Lymphoma (MALT) |
National Taiwan University Hospital |
2020-11-10 | PHASE2 |
| NCT02636322 | COMPLETED | Diffuse Large B-Cell Lymphoma Unclassifiable |
M.D. Anderson Cancer Center |
2016-03-29 | PHASE2 |
| NCT05014100 | UNKNOWN | B-cell Lymphoma |
Puyang Oilfield General Hospital |
2021-09-01 | PHASE2 |
| NCT02334865 | ACTIVE_NOT_RECRUITING | Partial Response of Multiple Myeloma or Plasma Cell Leukemia; Plasma Cell Myeloma |
Roswell Park Cancer Institute |
2017-04-13 | PHASE1 |
| NCT04120350 | UNKNOWN | Primary Central Nervous System Lymphoma |
Peking Union Medical College Hospital |
2019-08-16 | PHASE1; PHASE2 |
| NCT04430894 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Massachusetts General Hospital |
2020-07-10 | PHASE2 |
| NCT02215980 | COMPLETED | Multiple Myeloma |
Fondazione EMN Italy Onlus |
2014-07 | PHASE3 |
| NCT01754857 | COMPLETED | Lymphoid Leukemia; Small Lymphocytic Lymphoma; Lymphoma, Non-Hodgkin |
University of Wisconsin, Madison |
2013-11-12 | PHASE2 |
| NCT00551928 | COMPLETED | Multiple Myeloma; Newly Diagnosed Patients |
Fondazione EMN Italy Onlus |
2007-06 | PHASE3 |
| NCT03379051 | TERMINATED | Chronic Lymphocytic Leukemia; Non-Hodgkin Lymphoma |
TG Therapeutics, Inc. |
2018-03-27 | PHASE1; PHASE2 |
| NCT03477539 | COMPLETED | Plasma Cell Myeloma |
Mayo Clinic |
2018-04-09 | PHASE2 |
| NCT03113695 | COMPLETED | Richter's Syndrome; CLL |
University of California, San Diego |
2017-12-20 | PHASE1 |
| NCT02906332 | TERMINATED | Multiple Myeloma |
Hackensack Meridian Health |
2016-12-12 | PHASE2 |
| NCT03003520 | COMPLETED | Lymphoma, Large B-Cell, Diffuse |
Celgene |
2017-02-28 | PHASE2 |
| NCT02461888 | COMPLETED | Multiple Myeloma |
University of Leeds |
2015-12 | PHASE2 |
| NCT04329130 | UNKNOWN | Relapsed or Refractory Peripheral T-cell Lymphoma |
Sun Yat-sen University |
2020-03-27 | PHASE2 |
| NCT04277845 | UNKNOWN | Multiple Myeloma |
Samsung Medical Center |
2020-08-06 | PHASE2 |
| NCT04231370 | UNKNOWN | NK/T Cell Lymphoma Nos |
Beijing Tongren Hospital |
2020-04-01 | PHASE2 |
| NCT01208662 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Paul Richardson, MD |
2010-09 | PHASE3 |
| NCT02513186 | COMPLETED | Plasma Cell Myeloma |
Sanofi |
2015-09-30 | PHASE1 |
| NCT01554852 | UNKNOWN | Multiple Myeloma |
University of Leeds |
2010-05 | PHASE3 |
| NCT02126553 | COMPLETED | Alkylating Agent-Related Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia |
M.D. Anderson Cancer Center |
2014-11-13 | PHASE2 |
| NCT03314636 | ACTIVE_NOT_RECRUITING | Myeloma |
Oslo University Hospital |
2018-03-16 | PHASE2 |
| NCT01054196 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Weill Medical College of Cornell University |
2010-08 | PHASE1; PHASE2 |
| NCT02628405 | UNKNOWN | Recurrent B-Cell Non-Hodgkin Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Recurrent Transformed Non-Hodgkin Lymphoma; Refractory B-Cell Non-Hodgkin Lymphoma; Refractory Diffuse Large B-Cell Lymphoma; Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma; Refractory Transformed Non-Hodgkin Lymphoma |
Academic and Community Cancer Research United |
2016-05-20 | PHASE1; PHASE2 |
| NCT03015922 | UNKNOWN | Multiple Myeloma |
University of Leeds |
2017-06-05 | PHASE1 |
| NCT01091831 | COMPLETED | Multiple Myeloma |
Fondazione EMN Italy Onlus |
2009-07 | PHASE3 |
| NCT04065789 | COMPLETED | Myeloma Multiple; Myeloma, Plasma-Cell; Myeloma-Multiple; Plasma Cell Myeloma |
Tel-Aviv Sourasky Medical Center |
2018-05-02 | PHASE2 |
| NCT01038388 | COMPLETED | Multiple Myeloma |
Emory University |
2010-01-15 | PHASE1 |
| NCT03232307 | WITHDRAWN | CCND1 Positive; CD20-Positive Neoplastic Cells Present; Mantle Cell Lymphoma |
M.D. Anderson Cancer Center |
2019-07-01 | PHASE2 |
| NCT03416374 | COMPLETED | Relapsed and/or Refractory Multiple Myeloma |
Takeda |
2018-02-18 | PHASE4 |
| NCT00670358 | COMPLETED | Lymphoma |
Mayo Clinic |
2008-08-25 | PHASE1; PHASE2 |
| NCT01463670 | COMPLETED | Multiple Myeloma |
Memorial Sloan Kettering Cancer Center |
2011-10-28 | PHASE2 |
| NCT01583283 | COMPLETED | Multiple Myeloma |
Celgene |
2012-07-12 | PHASE1 |
| NCT03645395 | TERMINATED | Non-hodgkin Lymphoma |
Molecular Templates, Inc. |
2019-04-08 | PHASE2 |
| NCT03949062 | UNKNOWN | Diffuse Large B Cell Lymphoma |
Ruijin Hospital |
2019-03-13 | PHASE2 |
| NCT03151811 | TERMINATED | Multiple Myeloma |
Oncopeptides AB |
2017-06-12 | PHASE3 |
| NCT03891355 | UNKNOWN | Mantle Cell Lymphoma |
Fondazione Italiana Linfomi - ETS |
2019-09-30 | PHASE2 |
| NCT04040491 | UNKNOWN | Peripheral T-cell Lymphoma |
Mingzhi Zhang |
2019-09-01 | PHASE4 |
| NCT01208766 | COMPLETED | Multiple Myeloma |
Stichting Hemato-Oncologie voor Volwassenen Nederland |
2011-01 | PHASE3 |
| NCT01865110 | COMPLETED | Mantle Cell Lymphoma |
The Lymphoma Academic Research Organisation |
2013-11 | PHASE3 |
| NCT01886859 | COMPLETED | Recurrent B-Cell Prolymphocytic Leukemia; Recurrent Chronic Lymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory B-Cell Prolymphocytic Leukemia; Refractory Chronic Lymphocytic Leukemia; Refractory Small Lymphocytic Lymphoma |
National Cancer Institute (NCI) |
2013-04-26 | PHASE1 |
| NCT00774345 | COMPLETED | B-cell Chronic Lymphocytic Leukemia |
Celgene |
2009-01-27 | PHASE3 |
| NCT03283046 | WITHDRAWN | Malignant Neoplasms Stated as Primary Lymphoid Haematopoietic; Multiple Myeloma |
M.D. Anderson Cancer Center |
2017-10 | PHASE1 |
| NCT02802163 | WITHDRAWN | Multiple Myeloma |
H. Lee Moffitt Cancer Center and Research Institute |
2017-06 | PHASE1; PHASE2 |
| NCT03412565 | COMPLETED | Multiple Myeloma |
Janssen Research & Development, LLC |
2018-04-26 | PHASE2 |
| NCT00792077 | COMPLETED | Leukemia; CLL |
M.D. Anderson Cancer Center |
2008-11 | PHASE2 |
| NCT01054144 | COMPLETED | Multiple Myeloma |
H. Lee Moffitt Cancer Center and Research Institute |
2010-01-14 | PHASE2 |
| NCT02954406 | TERMINATED | Lymphoma, Non-Hodgkin |
Millennium Pharmaceuticals, Inc. |
2017-03-05 | PHASE1 |
| NCT01772420 | COMPLETED | Adult Myelodysplastic Syndrome; Anemia; Chronic Myelomonocytic Leukemia |
Albert Einstein College of Medicine |
2012-10 | PHASE2 |
| NCT03150316 | UNKNOWN | Myeloma, Multiple |
Chong Kun Dang Pharmaceutical |
2017-05-10 | PHASE1 |
| NCT01953692 | COMPLETED | Myelodysplastic Syndrome; Multiple Myeloma; Hodgkin Lymphoma; Non-Hodgkin Lymphoma; Diffuse Large B-Cell Lymphoma; Follicular Lymphoma; Primary Mediastinal B-Cell Lymphoma |
Merck Sharp & Dohme LLC |
2013-11-22 | PHASE1 |
| NCT02472691 | COMPLETED | Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic |
Heinrich-Heine University, Duesseldorf |
2015-05 | PHASE2 |
| NCT02626481 | COMPLETED | Multiple Myeloma |
University Hospital, Lille |
2015-12-28 | PHASE2 |
| NCT01788189 | COMPLETED | B-cell Lymphoma |
University Hospital, Essen |
2013-01 | PHASE1; PHASE2 |
| NCT01668719 | COMPLETED | DS Stage I Plasma Cell Myeloma; DS Stage II Plasma Cell Myeloma; DS Stage III Plasma Cell Myeloma |
SWOG Cancer Research Network |
2012-11 | PHASE1; PHASE2 |
| NCT02253316 | ACTIVE_NOT_RECRUITING | Multiple Myeloma |
Washington University School of Medicine |
2015-01-20 | PHASE2 |
| NCT04063189 | UNKNOWN | Multiple Myeloma in Relapse |
The First Hospital of Jilin University |
2017-03-21 | PHASE2 |
| NCT01208051 | COMPLETED | Refractory Differentiated Thyroid Gland Carcinoma; Refractory Thyroid Gland Follicular Carcinoma; Refractory Thyroid Gland Hurthle Cell Carcinoma; Refractory Thyroid Gland Papillary Carcinoma; Unresectable Thyroid Gland Carcinoma |
National Cancer Institute (NCI) |
2010-09-09 | PHASE1; PHASE2 |
| NCT01090089 | COMPLETED | Multiple Myeloma |
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH |
2010-03-01 | PHASE3 |
| NCT03795571 | UNKNOWN | Diffuse Large B-cell Lymphoma Recurrent; Diffuse Large B Cell Lymphoma Refractory |
The First Affiliated Hospital with Nanjing Medical University |
2019-01-01 | PHASE1 |
| NCT03440411 | TERMINATED | Multiple Myeloma |
Fondazione EMN Italy Onlus |
2016-02-18 | PHASE3 |
| NCT01850524 | COMPLETED | Multiple Myeloma |
Millennium Pharmaceuticals, Inc. |
2013-04-29 | PHASE3 |
| NCT01216683 | COMPLETED | Lymphoma |
ECOG-ACRIN Cancer Research Group |
2011-02-09 | PHASE2 |
| NCT02219178 | COMPLETED | Multiple Myeloma |
Cancer Trials Ireland |
2014-11 | PHASE2 |
| NCT01881789 | TERMINATED | Multiple Myeloma |
Amgen |
2013-10-28 | PHASE1; PHASE2 |
| NCT02966522 | UNKNOWN | Cardiac Amyloidosis |
Seoul National University Hospital |
2016-10 | PHASE2 |
| NCT02917941 | COMPLETED | Relapsed and/or Refractory Multiple Myeloma |
Takeda |
2016-11-01 | PHASE2 |
| NCT03359460 | COMPLETED | Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome; Refractory High Risk Myelodysplastic Syndrome; Secondary Myelodysplastic Syndrome; Therapy-Related Myelodysplastic Syndrome |
University of California, Davis |
2017-12-01 | PHASE1 |
| NCT03118466 | COMPLETED | AML |
Massachusetts General Hospital |
2017-09-25 | PHASE2 |
| NCT03785184 | WITHDRAWN | Multiple Myeloma |
AbbVie |
2019-04-29 | PHASE2 |
| NCT02612779 | COMPLETED | Multiple Myeloma |
Bristol-Myers Squibb |
2016-02-09 | PHASE2 |
| NCT02336815 | COMPLETED | Multiple Myeloma |
Karyopharm Therapeutics Inc |
2015-05-26 | PHASE2 |
| NCT02280525 | COMPLETED | Leukemia |
M.D. Anderson Cancer Center |
2015-03-05 | PHASE1 |
| NCT01858558 | COMPLETED | Multiple Myeloma |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2013-09 | PHASE2 |
| NCT03242460 | COMPLETED | Relapsed and/or refractorY Multiple Myeloma |
Kosin University Gospel Hospital |
2015-05-12 | PHASE2 |
| NCT03558750 | TERMINATED | Recurrent Central Nervous System Lymphoma; Recurrent Diffuse Large B-Cell Lymphoma; Refractory Central Nervous System Lymphoma; Refractory Diffuse Large B-Cell Lymphoma |
Vanderbilt-Ingram Cancer Center |
2018-06-14 | PHASE1 |
| NCT02705638 | COMPLETED | Immunoglobulin G Subclass 4 Related Disease; IgG4-related Disease; Autoimmune Pancreatitis; IgG4-related Sclerosing Cholangitis; Retroperitoneal Fibrosis |
Mayo Clinic |
2016-04 | PHASE1 |
| NCT02285062 | COMPLETED | Lymphoma, Large B-Cell, Diffuse |
Celgene |
2015-02-17 | PHASE3 |
| NCT01936532 | COMPLETED | Newly Diagnosed Multiple Myeloma |
Nantes University Hospital |
2014-11-12 | PHASE2 |
| NCT01440582 | COMPLETED | Myeloma |
M.D. Anderson Cancer Center |
2013-02-18 | PHASE1 |
| NCT04272775 | TERMINATED | Relapsed and/or Refractory Multiple Myeloma |
Takeda |
2012-06-05 | PHASE1 |
| NCT01125176 | COMPLETED | Chronic Lymphocytic Leukemia |
Weill Medical College of Cornell University |
2012-03-30 | PHASE2 |
| NCT01003769 | TERMINATED | Recurrent Chronic Lymphocytic Leukemia |
Mayo Clinic |
2015-07-09 | PHASE1; PHASE2 |
| NCT02279394 | COMPLETED | Smoldering Myeloma; Smoldering Multiple Myeloma |
Dana-Farber Cancer Institute |
2014-12-11 | PHASE2 |
| NCT02986451 | WITHDRAWN | Relapse/Refractory Multiple Myeloma |
Sun Yat-sen University |
2016-12 | PHASE2 |
| NCT02371577 | WITHDRAWN | Chronic Lymphocytic Leukemia (CLL) |
University of California, San Diego |
2017-02-01 | PHASE2 |
| NCT02128061 | COMPLETED | Diffuse Large B Cell Lymphoma |
The Lymphoma Academic Research Organisation |
2014-08 | PHASE3 |
| NCT01638936 | COMPLETED | Multiple Myeloma |
Biotest Pharmaceuticals Corporation |
2012-07-03 | PHASE1; PHASE2 |
| NCT02898259 | TERMINATED | B Cell Lymphoma; Lymphoma |
Brian Hill |
2017-02-20 | PHASE1; PHASE2 |
| NCT01729104 | TERMINATED | Lymphoma |
M.D. Anderson Cancer Center |
2013-04-25 | PHASE1 |
| NCT02928419 | TERMINATED | Myelodysplastic Syndromes |
Associazione Qol-one |
2015-05 | PHASE2 |
| NCT03333746 | TERMINATED | Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma |
Yvonne Efebera |
2018-03-21 | PHASE2 |
| NCT01582776 | COMPLETED | Follicular Lymphoma Patients (Phase IB); Follicular and Agressive (DLBCL&MCL) B-cell Lymphoma Patients (Phase II) |
The Lymphoma Academic Research Organisation |
2012-10-03 | PHASE1; PHASE2 |
| NCT02579863 | TERMINATED | Multiple Myeloma |
Merck Sharp & Dohme LLC |
2015-10-19 | PHASE3 |
| NCT00875667 | COMPLETED | Mantle Cell Lymphoma; Lymphoma, Mantle-Cell |
Celgene |
2009-04-30 | PHASE2 |
| NCT01433965 | COMPLETED | Acute Myeloid Leukemia; Myelodysplastic Syndrome |
University of California, Davis |
2012-08-08 | PHASE1 |
| NCT01816971 | COMPLETED | Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma |
University of Chicago |
2013-01 | PHASE2 |
| NCT00352794 | COMPLETED | Myelofibrosis |
M.D. Anderson Cancer Center |
2006-07-07 | PHASE2 |
| NCT01553786 | COMPLETED | T-cell Lymphoma |
The Lymphoma Academic Research Organisation |
2011-11 | PHASE2 |
| NCT02158702 | UNKNOWN | Multiple Myeloma; Relapse After Use of Lenalidomide and Bortezomib |
National University Hospital, Singapore |
2014-11 | PHASE2 |
| NCT02206425 | COMPLETED | Multiple Myeloma |
Oncotherapeutics |
2014-09 | PHASE1; PHASE2 |
| NCT02389543 | WITHDRAWN | Multiple Myeloma |
Karyopharm Therapeutics Inc |
2015-07 | PHASE1; PHASE2 |
| NCT01076543 | COMPLETED | AIDS-Related Hodgkin Lymphoma; Recurrent Adult Hodgkin Lymphoma; Recurrent Follicular Lymphoma; Recurrent Lymphoplasmacytic Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Non-Hodgkin Lymphoma; Recurrent T-Cell Non-Hodgkin Lymphoma; Waldenstrom Macroglobulinemia |
National Cancer Institute (NCI) |
2010-04-15 | PHASE1; PHASE2 |
| NCT01270932 | COMPLETED | Renal Failure; Multiple Myeloma |
University Health Network, Toronto |
2010-11 | PHASE2 |
| NCT02685826 | COMPLETED | Multiple Myeloma |
Celgene |
2016-04-25 | PHASE1; PHASE2 |
| NCT02963610 | TERMINATED | Relapsed or Refractory Solid Tumors; Nonsmall Cell Lung Cancer |
Fox Chase Cancer Center |
2017-03-29 | PHASE1; PHASE2 |
| NCT01939327 | COMPLETED | Non-Hodgkin Lymphoma |
Institut Paoli-Calmettes |
2013-09 | PHASE2 |
| NCT02406144 | COMPLETED | Multiple Myeloma |
PETHEMA Foundation |
2014-11 | PHASE3 |
| NCT03191981 | WITHDRAWN | Myeloma Multiple |
University of Leeds |
2017-08-01 | PHASE1; PHASE2 |
| NCT00963534 | COMPLETED | Mantle Cell Lymphoma |
Lund University Hospital |
2009-09 | PHASE1; PHASE2 |
| NCT02142049 | COMPLETED | Diffuse Large B Cell Lymphoma Relapsed; Diffuse Large B Cell Lymphoma Refractory |
Pharmacyclics LLC. |
2014-05 | PHASE1; PHASE2 |
| NCT02538965 | COMPLETED | Leukemia, Myeloid |
Celgene |
2015-11-19 | PHASE2 |
| NCT02655458 | COMPLETED | Multiple Myeloma |
Hearn Jay Cho |
2016-01 | PHASE1 |
| NCT00891384 | COMPLETED | Multiple Myeloma |
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH |
2009-04-01 | PHASE3 |
| NCT02086604 | COMPLETED | Lymphoma, Large B-Cell, Diffuse |
Washington University School of Medicine |
2014-09-18 | PHASE1 |
| NCT01460420 | COMPLETED | Hematologic Malignancies; Multiple Myeloma |
European Myeloma Network B.V. |
2011-11 | PHASE1; PHASE2 |
| NCT01731886 | COMPLETED | Multiple Myeloma |
Columbia University |
2012-09 | PHASE4 |
| NCT03000634 | WITHDRAWN | Multiple Myeloma |
University of Arkansas |
2017-04-01 | PHASE2 |
| NCT02200848 | TERMINATED | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
Georgetown University |
2014-04 | PHASE1 |
| NCT01924169 | TERMINATED | Hematologic Disorder |
M.D. Anderson Cancer Center |
2014-11-24 | PHASE2 |
| NCT01352962 | COMPLETED | Urethral Neoplasms; Neoplasms, Urethral; Cancer of the Urethra; Urethral Cancer |
National Cancer Institute (NCI) |
2011-09-26 | PHASE1 |
| NCT01109004 | COMPLETED | Multiple Myeloma |
National Heart, Lung, and Blood Institute (NHLBI) |
2010-05 | PHASE3 |
| NCT02446236 | ACTIVE_NOT_RECRUITING | Mantle Cell Lymphoma |
Hackensack Meridian Health |
2015-06-18 | PHASE1 |
| NCT01518465 | TERMINATED | Stage I Multiple Myeloma; Stage II Multiple Myeloma; Stage III Multiple Myeloma |
University of Southern California |
2012-01-09 | PHASE2 |
| NCT01827137 | COMPLETED | Multiple Myeloma |
Sellas Life Sciences Group |
2013-04 | PHASE1; PHASE2 |
| NCT01133743 | COMPLETED | Chronic Lymphocytic Leukemia |
University Health Network, Toronto |
2010-05 | PHASE2 |
| NCT01460940 | COMPLETED | Adult Lymphocyte Depletion Hodgkin Lymphoma; Adult Lymphocyte Predominant Hodgkin Lymphoma; Adult Mixed Cellularity Hodgkin Lymphoma; Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma; Adult Nodular Sclerosis Hodgkin Lymphoma; Recurrent Adult Hodgkin Lymphoma |
Ohio State University Comprehensive Cancer Center |
2011-10-13 | PHASE2 |
| NCT01794039 | COMPLETED | Recurrent Plasma Cell Myeloma; Refractory Plasma Cell Myeloma |
Mayo Clinic |
2014-03 | PHASE2 |
| NCT01545804 | COMPLETED | Liver Cancer |
National Taiwan University Hospital |
2011-08 | PHASE2 |
| NCT01349569 | COMPLETED | Multiple Myeloma |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2012-01 | PHASE2 |
| NCT02348528 | COMPLETED | Multiple Myeloma |
Celgene |
2012-09-11 | PHASE2 |
| NCT00540007 | COMPLETED | Hodgkin Disease |
Washington University School of Medicine |
2007-09-06 | PHASE2 |
| NCT02340936 | COMPLETED | Diffuse Large B-cell Lymphoma |
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea |
2011-01 | PHASE1; PHASE2 |
| NCT01559935 | COMPLETED | Multiple Myeloma |
Weill Medical College of Cornell University |
2012-04-19 | PHASE2 |
| NCT01578954 | COMPLETED | Acute Myeloid Leukemia |
UNC Lineberger Comprehensive Cancer Center |
2012-06-28 | PHASE1 |
| NCT01675141 | TERMINATED | Multiple Myeloma |
National Cancer Institute (NCI) |
2012-08-20 | PHASE2 |
| NCT00874978 | COMPLETED | Myelodysplastic Syndromes |
King's College Hospital NHS Trust |
2005-01 | PHASE2 |
| NCT01183663 | COMPLETED | Advanced Cancers |
M.D. Anderson Cancer Center |
2010-08 | PHASE1 |
| NCT00737529 | COMPLETED | Mantle Cell Lymphoma |
Celgene |
2008-12-22 | PHASE2 |
| NCT01861340 | COMPLETED | Myeloma |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2014-05 | EARLY_PHASE1 |
| NCT01359657 | COMPLETED | Multiple Myeloma |
Bristol-Myers Squibb |
2011-09 | PHASE1 |
| NCT01556776 | COMPLETED | Chronic Lymphocytic Leukemia |
German CLL Study Group |
2012-07-20 | PHASE3 |
| NCT00294632 | COMPLETED | Lymphoma |
M.D. Anderson Cancer Center |
2006-02 | PHASE1; PHASE2 |
| NCT00727415 | COMPLETED | Chronic Lymphocytic Leukemia |
Gruppo Italiano Malattie EMatologiche dell'Adulto |
2008-02 | PHASE1; PHASE2 |
| NCT01450215 | COMPLETED | Multiple Myeloma |
Karolinska University Hospital |
2011-03 | PHASE2 |
| NCT00933426 | TERMINATED | Prostate Cancer |
M.D. Anderson Cancer Center |
2009-08 | PHASE1 |
| NCT01215344 | COMPLETED | Multiple Myeloma |
Vanderbilt-Ingram Cancer Center |
2010-11 | PHASE2 |
| NCT02075021 | TERMINATED | Relapsed or Refractory Multiple Myeloma |
NYU Langone Health |
2014-03 | PHASE1; PHASE2 |
| NCT01673308 | UNKNOWN | Myelodysplastic Syndrome |
Ulsan University Hospital |
2012-08 | PHASE2 |
| NCT01629082 | COMPLETED | Myeldysplastic Syndrome (MDS); Chronic Myelomonocytic Leukemia; Bone Marrow Diseases; Neutropenia; Acute Myeloid Leukemia (AML) |
National Heart, Lung, and Blood Institute (NHLBI) |
2012-06-06 | PHASE1 |
| NCT01615029 | COMPLETED | Multiple Myeloma |
Janssen Research & Development, LLC |
2012-06-26 | PHASE1; PHASE2 |
| NCT01816620 | COMPLETED | POEMS Syndrome |
Peking Union Medical College Hospital |
2014-03 | PHASE2 |
| NCT02193698 | COMPLETED | POEMS Syndrome |
Chiba University |
2014-07 | PHASE2 |
| NCT00632359 | COMPLETED | Chronic Lymphocytic Leukemia |
M.D. Anderson Cancer Center |
2008-02 | PHASE2 |
| NCT02521714 | COMPLETED | Healthy Volunteers |
Celgene |
2015-08-14 | PHASE1 |
| NCT01985477 | TERMINATED | Myeloma |
M.D. Anderson Cancer Center |
2013-12 | PHASE1 |
| NCT01412307 | UNKNOWN | Recurrent Adult Hodgkin Lymphoma |
Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale |
2011-07 | PHASE1; PHASE2 |
| NCT01647165 | WITHDRAWN | Multiple Myeloma |
National Cancer Institute (NCI) |
2012-07-11 | PHASE2 |
| NCT00096044 | COMPLETED | Leukemia |
Roswell Park Cancer Institute |
2004-03 | PHASE2 |
| NCT01358734 | COMPLETED | Acute Myeloid Leukemia; Acute Myelogenous Leukemia |
Celgene |
2012-04-27 | PHASE2 |
| NCT01093183 | TERMINATED | Adenocarcinoma of the Prostate; Hormone-resistant Prostate Cancer; Recurrent Prostate Cancer |
University of Nebraska |
2010-03-04 | PHASE1; PHASE2 |
| NCT01904643 | TERMINATED | Adult Acute Megakaryoblastic Leukemia (M7); Adult Acute Minimally Differentiated Myeloid Leukemia (M0); Adult Acute Monoblastic Leukemia (M5a); Adult Acute Monocytic Leukemia (M5b); Adult Acute Myeloblastic Leukemia With Maturation (M2); Adult Acute Myeloblastic Leukemia Without Maturation (M1); Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities; Adult Acute Myeloid Leukemia With Del(5q); Adult Acute Myeloid Leukemia With Inv(16)(p13;q22); Adult Acute Myeloid Leukemia With t(16;16)(p13;q22); Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); Adult Acute Myelomonocytic Leukemia (M4); Adult Erythroleukemia (M6a); Adult Pure Erythroid Leukemia (M6b); Recurrent Adult Acute Myeloid Leukemia |
Stanford University |
2014-02 | PHASE1 |
| NCT01368757 | UNKNOWN | Chronic Myelomonocytic Leukemia |
Arbeitsgemeinschaft medikamentoese Tumortherapie |
2010-06 | PHASE1; PHASE2 |
| NCT00957385 | COMPLETED | Acute Myeloid Leukemia |
University Health Network, Toronto |
2008-06 | PHASE2 |
| NCT02206503 | COMPLETED | Multiple Myeloma |
Fondazione EMN Italy Onlus |
2013-03 | PHASE2 |
| NCT01617213 | TERMINATED | Multiple Myeloma |
University of Virginia |
2012-04 | PHASE2 |
| NCT01604031 | TERMINATED | B-cell Chronic Lymphocytic Leukemia |
Baylor College of Medicine |
2013-02 | PHASE1 |
| NCT01703364 | COMPLETED | CLL; Chronic Lymphocytic Leukemia |
Arbeitsgemeinschaft medikamentoese Tumortherapie |
2012-06 | PHASE1; PHASE2 |
| NCT01373294 | COMPLETED | Bladder Cancer |
H. Lee Moffitt Cancer Center and Research Institute |
2011-11-30 | PHASE2 |
| NCT02525250 | COMPLETED | Acute Myeloid Leukemia or Myelodysplasic Syndrome |
Institut Paoli-Calmettes |
2012-12 | |
| NCT01403246 | TERMINATED | Chronic Lymphocytic Leukemia |
Gruppo Italiano Malattie EMatologiche dell'Adulto |
2011-11 | PHASE1; PHASE2 |
| NCT02038153 | TERMINATED | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Adult Acute Myeloid Leukemia in Remission |
Albert Einstein College of Medicine |
2013-12 | PHASE1; PHASE2 |
| NCT01111903 | COMPLETED | Ovarian Cancer Recurrent |
ARCAGY/ GINECO GROUP |
2009-05 | PHASE1; PHASE2 |
| NCT00466895 | COMPLETED | Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Chronic Lymphocytic Leukemia |
Leslie Andritsos |
2007-04 | PHASE1 |
| NCT01241734 | COMPLETED | Diffuse Large B Cell Lymphoma |
Hackensack Meridian Health |
2010-10 | PHASE1; PHASE2 |
| NCT00765245 | COMPLETED | Lymphoma |
Vanderbilt-Ingram Cancer Center |
2008-10 | PHASE2 |
| NCT01352338 | COMPLETED | Multiple Myeloma |
UMC Utrecht |
2011-08 | PHASE1; PHASE2 |
| NCT00864942 | COMPLETED | Chronic Lymphocytic Leukemia; Non-Hodgkin's Lymphoma |
Georgetown University |
2009-02 | PHASE1 |
| NCT01239797 | COMPLETED | Lymphoma; Multiple Myeloma |
Bristol-Myers Squibb |
2011-06-20 | PHASE3 |
| NCT01704781 | COMPLETED | HIV-1 Infection |
Bionor Immuno AS |
2012-09 | PHASE1; PHASE2 |
| NCT01644799 | COMPLETED | Recurrent Follicular Lymphoma |
Alliance for Clinical Trials in Oncology |
2013-08-02 | PHASE1 |
| NCT01645930 | COMPLETED | Multiple Myeloma |
Millennium Pharmaceuticals, Inc. |
2012-12-17 | PHASE1 |
| NCT00759603 | COMPLETED | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
M.D. Anderson Cancer Center |
2008-09 | PHASE2 |
| NCT01737177 | COMPLETED | Mantle Cell Lymphoma |
Fondazione Italiana Linfomi - ETS |
2012-07-31 | PHASE2 |
| NCT01484626 | TERMINATED | Multiple Myeloma |
Loyola University |
2011-05-05 | PHASE1; PHASE2 |
| NCT01080391 | COMPLETED | Relapsed Multiple Myeloma |
Amgen |
2010-07-14 | PHASE3 |
| NCT01246076 | COMPLETED | Myelodysplastic Syndromes |
Washington University School of Medicine |
2011-06 | PHASE2 |
| NCT00902915 | UNKNOWN | Multiple Myeloma Light Chain Induced Renal Insufficiency |
Austrian Forum Against Cancer |
2009-05 | PHASE2 |
| NCT00867308 | TERMINATED | Myelodysplastic Syndrome |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2009-07 | PHASE2 |
| NCT01472562 | COMPLETED | Mantle Cell Lymphoma |
Weill Medical College of Cornell University |
2011-07-29 | PHASE2 |
| NCT00910910 | COMPLETED | B-Cell Chronic Lymphocytic Leukemia |
Celgene |
2009-10-13 | PHASE3 |
| NCT01393964 | COMPLETED | Multiple Myeloma |
Bristol-Myers Squibb |
2012-01-06 | PHASE1 |
| NCT00915408 | COMPLETED | Multiple Myeloma |
King's College Hospital NHS Trust |
2006-09 | PHASE1; PHASE2 |
| NCT01537861 | TERMINATED | Multiple Myeloma |
Washington University School of Medicine |
2012-06 | EARLY_PHASE1 |
| NCT01282047 | TERMINATED | HIV Infection Associated Kaposi Disease |
French National Agency for Research on AIDS and Viral Hepatitis |
2011-10 | PHASE2 |
| NCT00671801 | TERMINATED | Malignant Gliomas |
M.D. Anderson Cancer Center |
2008-04-29 | PHASE1 |
| NCT01254617 | COMPLETED | Recurrent Colon Carcinoma; Recurrent Hypopharyngeal Squamous Cell Carcinoma; Recurrent Laryngeal Squamous Cell Carcinoma; Recurrent Laryngeal Verrucous Carcinoma; Recurrent Lip and Oral Cavity Squamous Cell Carcinoma; Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary; Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma; Recurrent Nasopharyngeal Keratinizing Squamous Cell Carcinoma; Recurrent Oral Cavity Verrucous Carcinoma; Recurrent Oropharyngeal Squamous Cell Carcinoma; Recurrent Rectal Carcinoma; Recurrent Salivary Gland Carcinoma; Salivary Gland Squamous Cell Carcinoma; Squamous Cell Carcinoma Metastatic in the Neck With Occult Primary; Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7; Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7; Stage IVA Colon Cancer AJCC v7; Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7; Stage IVA Laryngeal Verrucous Carcinoma AJCC v7; Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage IVA Major Salivary Gland Cancer AJCC v7; Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7; Stage IVA Oral Cavity Cancer AJCC v6 and v7; Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7; Stage IVA Rectal Cancer AJCC v7; Stage IVB Colon Cancer AJCC v7; Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7; Stage IVB Laryngeal Verrucous Carcinoma AJCC v7; Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage IVB Major Salivary Gland Cancer AJCC v7; Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7; Stage IVB Oral Cavity Cancer AJCC v6 and v7; Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7; Stage IVB Rectal Cancer AJCC v7; Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7; Stage IVC Laryngeal Verrucous Carcinoma AJCC v7; Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7; Stage IVC Major Salivary Gland Cancer AJCC v7; Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v7; Stage IVC Oral Cavity Cancer AJCC v6 and v7; Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7; Tongue Carcinoma |
National Cancer Institute (NCI) |
2011-02-10 | PHASE1 |
| NCT02983097 | TERMINATED | Diffuse Large B-cell Lymphoma (DLBCL); Follicular Lymphoma Grade III (FL III°); Mantle Cell Lymphoma (MCL), Blastoid Variant; Burkitt Lymphoma (BL); Aggressive Marginal Zone Lymphoma (MZL) |
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH |
2010-11 | PHASE1; PHASE2 |
| NCT01132586 | COMPLETED | Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome; Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11; Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1; Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL; Adult Acute Promyelocytic Leukemia With t(15;17)(q22;q12); PML-RARA; Alkylating Agent-Related Acute Myeloid Leukemia; de Novo Myelodysplastic Syndrome; Previously Treated Myelodysplastic Syndrome; Recurrent Adult Acute Myeloid Leukemia; Secondary Acute Myeloid Leukemia; Secondary Myelodysplastic Syndrome; Untreated Adult Acute Myeloid Leukemia |
National Cancer Institute (NCI) |
2010-05 | PHASE1 |
| NCT01547260 | COMPLETED | Pancreatic Carcinoma Metastatic; Pancreatic Ductal Adenocarcinoma |
Maria Liljefors |
2009-10 | PHASE1; PHASE2 |
| NCT01019174 | COMPLETED | Multiple Myeloma |
Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH |
2009-11 | PHASE1; PHASE2 |
| NCT01217203 | COMPLETED | Patients With Multiple Myeloma Experiencing a; First or Second Relapse |
Innate Pharma |
2010-09 | PHASE1 |
| NCT01698801 | COMPLETED | Multiple Myeloma |
Celgene |
2012-10-01 | PHASE2 |
| NCT00622336 | COMPLETED | Multiple Myeloma |
Celgene |
2003-04-01 | PHASE3 |
| NCT01379274 | TERMINATED | MDS |
Rush University Medical Center |
2011-01 | PHASE2 |
| NCT01465230 | TERMINATED | Chronic Lymphocytic Leukemia |
Yale University |
2012-03 | PHASE2 |
| NCT01558167 | COMPLETED | Chronic Lymphocytic Leukemia |
German CLL Study Group |
2011-02 | PHASE1; PHASE2 |
| NCT00784927 | COMPLETED | Lymphoma |
Mayo Clinic |
2008-11 | PHASE2 |
| NCT01378091 | COMPLETED | Prostate Cancer |
Columbia University |
2005-08 | PHASE1 |
| NCT01197560 | COMPLETED | Diffuse Large B-cell Lymphoma |
Celgene |
2010-09-02 | PHASE2; PHASE3 |
| NCT01200004 | TERMINATED | Advanced Cancers |
M.D. Anderson Cancer Center |
2012-04 | PHASE1 |
| NCT01393756 | COMPLETED | Follicular Lymphoma |
The Lymphoma Academic Research Organisation |
2010-12 | PHASE2 |
| NCT00603447 | COMPLETED | Relapsed Multiple Myeloma |
Amgen |
2008-05 | PHASE1 |
| NCT00617591 | COMPLETED | Multiple Myeloma |
H. Lee Moffitt Cancer Center and Research Institute |
2008-01 | PHASE2 |
| NCT00536341 | COMPLETED | Chronic Lymphocytic Leukemia |
SCRI Development Innovations, LLC |
2008-01 | PHASE1; PHASE2 |
| NCT01348919 | COMPLETED | Multiple Myeloma |
Teva Branded Pharmaceutical Products R&D, Inc. |
2011-08-03 | PHASE1; PHASE2 |
| NCT01217957 | COMPLETED | Multiple Myeloma |
Millennium Pharmaceuticals, Inc. |
2010-11-22 | PHASE1; PHASE2 |
| NCT01121757 | TERMINATED | Follicular Lymphoma; Marginal Zone Lymphoma |
Duke University |
2010-04 | PHASE2 |
| NCT00735930 | COMPLETED | Anemia; Chronic Lymphocytic Leukemia; Prolymphocytic Leukemia; Recurrent Small Lymphocytic Lymphoma; Refractory Chronic Lymphocytic Leukemia; Thrombocytopenia |
National Cancer Institute (NCI) |
2008-08 | PHASE1 |
| NCT00535873 | COMPLETED | Leukemia; CLL; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma |
M.D. Anderson Cancer Center |
2007-10 | PHASE2 |
| NCT01422486 | TERMINATED | Myelodysplastic Syndrome (MDS) |
Telik |
2011-10 | PHASE2 |
| NCT00114101 | ACTIVE_NOT_RECRUITING | DS Stage I Multiple Myeloma; DS Stage II Multiple Myeloma; DS Stage III Multiple Myeloma; Refractory Multiple Myeloma; Smoldering Multiple Myeloma |
National Cancer Institute (NCI) |
2004-12-15 | PHASE3 |
| NCT01145495 | COMPLETED | Ann Arbor Stage II Grade 1 Contiguous Follicular Lymphoma; Ann Arbor Stage II Grade 1 Non-Contiguous Follicular Lymphoma; Ann Arbor Stage II Grade 2 Contiguous Follicular Lymphoma; Ann Arbor Stage II Grade 2 Non-Contiguous Follicular Lymphoma; Ann Arbor Stage II Grade 3 Contiguous Follicular Lymphoma; Ann Arbor Stage II Grade 3 Non-Contiguous Follicular Lymphoma; Ann Arbor Stage III Grade 1 Follicular Lymphoma; Ann Arbor Stage III Grade 2 Follicular Lymphoma; Ann Arbor Stage III Grade 3 Follicular Lymphoma; Ann Arbor Stage IV Grade 1 Follicular Lymphoma; Ann Arbor Stage IV Grade 2 Follicular Lymphoma; Ann Arbor Stage IV Grade 3 Follicular Lymphoma |
National Cancer Institute (NCI) |
2010-06-15 | PHASE2 |
| NCT01185262 | COMPLETED | Chronic Lymphocytic Leukemia |
MD Anderson International Spain SA |
2009-04 | PHASE1 |
| NCT00691704 | COMPLETED | Multiple Myeloma |
Cristina Gasparetto |
2008-08 | PHASE2 |
| NCT01348503 | TERMINATED | Hepatocellular Carcinoma |
Indiana University |
2011-05 | PHASE1 |
| NCT00495872 | COMPLETED | Solid Tumors |
M.D. Anderson Cancer Center |
2007-06 | PHASE1 |
| NCT00642954 | COMPLETED | Relapsed or Refractory Multiple Myeloma |
Merck Sharp & Dohme LLC |
2008-02-13 | PHASE1 |
| NCT01127386 | COMPLETED | Cancer Cachexia Syndrome |
Florian Strasser, MD ABHPM |
2009-03 | PHASE1; PHASE2 |
| NCT01194791 | COMPLETED | Primary Systemic Amyloidosis |
PETHEMA Foundation |
2010-10 | PHASE2 |
| NCT00654186 | COMPLETED | Prostate Cancer |
Oncology Specialists, S.C. |
2008-02 | PHASE2 |
| NCT00972842 | TERMINATED | Peripheral T-Cell Non-Hodgkin's Lymphoma |
Arbeitsgemeinschaft medikamentoese Tumortherapie |
2009-09 | PHASE1; PHASE2 |
| NCT00091260 | COMPLETED | Multiple Myeloma |
Vaishali Sanchorawala |
2004-01 | PHASE2 |
| NCT00360672 | COMPLETED | Acute Myelogenous Leukemia; Myelodysplastic Syndrome |
M.D. Anderson Cancer Center |
2009-01 | PHASE2 |
| NCT00884546 | COMPLETED | Advanced Cancer, Various, NOS |
Bristol-Myers Squibb |
2009-07 | PHASE1 |
| NCT01501370 | WITHDRAWN | Multiple Myeloma |
Tiziana Marangon |
2012-01 | PHASE2 |
| NCT01029054 | COMPLETED | Multiple Myeloma |
University of Michigan Rogel Cancer Center |
2009-09 | PHASE1; PHASE2 |
| NCT00975806 | TERMINATED | Renal Cell Carcinoma |
Celgene |
2009-09-01 | PHASE1; PHASE2 |
| NCT02353468 | TERMINATED | Refractory Plasma Cell Myeloma |
University of Colorado, Denver |
2009-12 | PHASE2 |
| NCT00352001 | COMPLETED | Leukemia; Myelodysplastic Syndromes |
Mikkael Sekeres MD |
2006-05 | PHASE1; PHASE2 |
| NCT01166035 | UNKNOWN | Solid Tumors |
Medical University Innsbruck |
2010-03 | PHASE1; PHASE2 |
| NCT01271283 | WITHDRAWN | Chronic Lymphocytic Leukemia; Stage III Chronic Lymphocytic Leukemia; Stage IV Chronic Lymphocytic Leukemia |
National Cancer Institute (NCI) |
2010-12 | PHASE2 |
| NCT00903630 | TERMINATED | Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer |
Masonic Cancer Center, University of Minnesota |
2009-04 | PHASE1; PHASE2 |
| NCT01055301 | WITHDRAWN | Multiple Myeloma; Plasma Cell Myeloma |
SWOG Cancer Research Network |
2011-07 | PHASE2 |
| NCT00923663 | UNKNOWN | MALT Lymphoma |
Medical University of Vienna |
2009-07 | PHASE2 |
| NCT00890929 | COMPLETED | Acute Myeloid Leukemia (AML); Adult Acute Myeloblastic Leukemia |
Stanford University |
2009-04 | PHASE1; PHASE2 |
| NCT00665652 | TERMINATED | Neuropathy; Nonmalignant Monoclonal Gammopathy of Undetermined Significance (MGUS) |
Dartmouth-Hitchcock Medical Center |
2008-04 | PHASE2 |
| NCT01180569 | WITHDRAWN | Lymphoma; Follicular Lymphoma |
Memorial Sloan Kettering Cancer Center |
2010-08 | PHASE1; PHASE2 |
| NCT00413036 | COMPLETED | Lymphoma, Non-Hodgkin's |
Celgene |
2006-06 | PHASE2 |
| NCT00860457 | COMPLETED | Chronic Lymphocytic Leukemia |
Georgetown University |
2008-02 | PHASE2 |
| NCT01045928 | TERMINATED | Adult Non-Hodgkin Lymphoma; Adult Grade III Lymphomatoid Granulomatosis; Contiguous Stage II Adult Burkitt Lymphoma; Contiguous Stage II Adult Diffuse Large Cell Lymphoma; Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Contiguous Stage II Adult Lymphoblastic Lymphoma; Contiguous Stage II Grade 1 Follicular Lymphoma; Contiguous Stage II Grade 2 Follicular Lymphoma; Contiguous Stage II Grade 3 Follicular Lymphoma; Contiguous Stage II Mantle Cell Lymphoma; Contiguous Stage II Marginal Zone Lymphoma; Contiguous Stage II Small Lymphocytic Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Nodal Marginal Zone B-cell Lymphoma; Noncontiguous Stage II Adult Burkitt Lymphoma; Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma; Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma; Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma; Noncontiguous Stage II Adult Lymphoblastic Lymphoma; Noncontiguous Stage II Grade 1 Follicular Lymphoma; Noncontiguous Stage II Grade 2 Follicular Lymphoma; Noncontiguous Stage II Grade 3 Follicular Lymphoma; Noncontiguous Stage II Mantle Cell Lymphoma; Noncontiguous Stage II Marginal Zone Lymphoma; Noncontiguous Stage II Small Lymphocytic Lymphoma; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Small Lymphocytic Lymphoma; Splenic Marginal Zone Lymphoma; Stage I Adult Burkitt Lymphoma; Stage I Adult Diffuse Large Cell Lymphoma; Stage I Adult Diffuse Mixed Cell Lymphoma; Stage I Adult Diffuse Small Cleaved Cell Lymphoma; Stage I Adult Immunoblastic Large Cell Lymphoma; Stage I Adult Lymphoblastic Lymphoma; Stage I Grade 1 Follicular Lymphoma; Stage I Grade 2 Follicular Lymphoma; Stage I Grade 3 Follicular Lymphoma; Stage I Mantle Cell Lymphoma; Stage I Marginal Zone Lymphoma; Stage I Small Lymphocytic Lymphoma; Stage III Adult Burkitt Lymphoma; Stage III Adult Diffuse Large Cell Lymphoma; Stage III Adult Diffuse Mixed Cell Lymphoma; Stage III Adult Diffuse Small Cleaved Cell Lymphoma; Stage III Adult Immunoblastic Large Cell Lymphoma; Stage III Adult Lymphoblastic Lymphoma; Stage III Grade 1 Follicular Lymphoma; Stage III Grade 2 Follicular Lymphoma; Stage III Grade 3 Follicular Lymphoma; Stage III Mantle Cell Lymphoma; Stage III Marginal Zone Lymphoma; Stage III Small Lymphocytic Lymphoma; Stage IV Adult Burkitt Lymphoma; Stage IV Adult Diffuse Large Cell Lymphoma; Stage IV Adult Diffuse Mixed Cell Lymphoma; Stage IV Adult Diffuse Small Cleaved Cell Lymphoma; Stage IV Adult Immunoblastic Large Cell Lymphoma; Stage IV Adult Lymphoblastic Lymphoma; Stage IV Grade 1 Follicular Lymphoma; Stage IV Grade 2 Follicular Lymphoma; Stage IV Grade 3 Follicular Lymphoma; Stage IV Mantle Cell Lymphoma; Stage IV Marginal Zone Lymphoma; Stage IV Small Lymphocytic Lymphoma; Waldenstrom Macroglobulinemia |
Case Comprehensive Cancer Center |
2010-01 | PHASE1 |
| NCT00981708 | COMPLETED | Amyloidosis |
University of Athens |
2008-02 | PHASE1; PHASE2 |
| NCT02041325 | COMPLETED | Plasma Cell Disorder |
Boston VA Research Institute, Inc. |
2005-04 | PHASE2 |
| NCT00699842 | TERMINATED | Myelodysplastic Syndrome; MDS; Low to Intermediate-1 MDS; Non-deletion 5q |
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
2008-07 | PHASE1; PHASE2 |
| NCT00907452 | COMPLETED | Myeloma |
Intergroupe Francophone du Myelome |
2009-07-29 | |
| NCT00840827 | TERMINATED | Myelodysplastic Syndrome |
Weill Medical College of Cornell University |
2008-12 | PHASE2 |
| NCT00602836 | COMPLETED | Leukemia; Lymphoma |
Mayo Clinic |
2008-02 | PHASE2 |
| NCT00227591 | COMPLETED | Essential Thrombocythemia; Polycythemia Vera; Primary Myelofibrosis |
National Cancer Institute (NCI) |
2005-12 | PHASE2 |
| NCT00460031 | COMPLETED | Prostate Cancer |
Case Comprehensive Cancer Center |
2006-09-01 | PHASE2 |
| NCT00482261 | COMPLETED | Multiple Myeloma |
Peter MacCallum Cancer Centre, Australia |
2007-06 | PHASE2 |
| NCT01408199 | COMPLETED | Cutaneous Lupus |
Hospital Universitari Vall d'Hebron Research Institute |
2010-01 | PHASE4 |
| NCT00287287 | COMPLETED | Thyroid Neoplasms |
Kenneth Ain |
2006-02 | PHASE2 |
| NCT00538733 | COMPLETED | Multiple Myeloma |
Weill Medical College of Cornell University |
2007-10 | PHASE2 |
| NCT01222195 | TERMINATED | Leukemia |
M.D. Anderson Cancer Center |
2008-02 | PHASE2 |
| NCT00786851 | COMPLETED | MANTLE CELL LYMPHOMA |
Fondazione Italiana Linfomi - ETS |
2008-07 | PHASE2 |
| NCT01116154 | TERMINATED | Adult Nasal Type Extranodal NK/T-cell Lymphoma; Anaplastic Large Cell Lymphoma; Angioimmunoblastic T-cell Lymphoma; Cutaneous B-cell Non-Hodgkin Lymphoma; Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue; Hepatosplenic T-cell Lymphoma; Intraocular Lymphoma; Nodal Marginal Zone B-cell Lymphoma; Peripheral T-Cell Lymphoma; Post-transplant Lymphoproliferative Disorder; Recurrent Adult Burkitt Lymphoma; Recurrent Adult Diffuse Large Cell Lymphoma; Recurrent Adult Diffuse Mixed Cell Lymphoma; Recurrent Adult Diffuse Small Cleaved Cell Lymphoma; Recurrent Adult Grade III Lymphomatoid Granulomatosis; Recurrent Adult Hodgkin Lymphoma; Recurrent Adult Immunoblastic Large Cell Lymphoma; Recurrent Adult Lymphoblastic Lymphoma; Recurrent Adult T-cell Leukemia/Lymphoma; Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma; Recurrent Grade 1 Follicular Lymphoma; Recurrent Grade 2 Follicular Lymphoma; Recurrent Grade 3 Follicular Lymphoma; Recurrent Mantle Cell Lymphoma; Recurrent Marginal Zone Lymphoma; Recurrent Mycosis Fungoides/Sezary Syndrome; Recurrent Small Lymphocytic Lymphoma; Small Intestine Lymphoma; Splenic Marginal Zone Lymphoma; Testicular Lymphoma; Waldenstrom Macroglobulinemia |
City of Hope Medical Center |
2010-05 | PHASE1 |
| NCT00837031 | COMPLETED | Metastatic Pancreatic Cancer |
SCRI Development Innovations, LLC |
2009-02 | PHASE2 |
| NCT00525447 | COMPLETED | Multiple Myeloma |
Seagen Inc. |
2007-08 | PHASE1 |
| NCT00968331 | TERMINATED | Diffuse Large B-cell Lymphoma |
University of Bologna |
2009-03 | PHASE2 |
| NCT00761449 | COMPLETED | MDS; AML |
Nordic MDS Group |
2007-10 | PHASE2 |
| NCT00621400 | COMPLETED | Amyloidosis |
Nantes University Hospital |
2008-01 | PHASE1; PHASE2 |
| NCT00729638 | COMPLETED | Multiple Myeloma |
Massachusetts General Hospital |
2008-06 | PHASE1 |
| NCT00633945 | COMPLETED | Cutaneous Lupus Erythematosus (CLE) |
University of Pennsylvania |
2007-11 | |
| NCT00704691 | TERMINATED | Peripheral T-cell Lymphomas; Adult T-cell Leukemia; Adult T-cell Lymphoma; Peripheral T-cell Lymphoma Unspecified; Angioimmunoblastic T-cell Lymphoma; Anaplastic Large Cell Lymphoma; T/Null Cell Systemic Type; Cutaneous t-Cell Lymphoma With Nodal/Visceral Disease |
University of Alabama at Birmingham |
2008-06 | EARLY_PHASE1 |
| NCT00104962 | COMPLETED | Childhood Myelodysplastic Syndromes; de Novo Myelodysplastic Syndromes; Previously Treated Myelodysplastic Syndromes; Refractory Anemia; Refractory Anemia With Excess Blasts; Refractory Anemia With Ringed Sideroblasts; Refractory Cytopenia With Multilineage Dysplasia; Secondary Myelodysplastic Syndromes; Unspecified Childhood Solid Tumor, Protocol Specific |
National Cancer Institute (NCI) |
2005-03 | PHASE1 |
| NCT00445484 | COMPLETED | Multiple Myeloma and Plasma Cell Neoplasm |
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
2007-01 | PHASE2 |
| NCT00109005 | COMPLETED | Melanoma |
National Cancer Institute (NCI) |
2005-04 | PHASE2 |
| NCT00418665 | COMPLETED | Myelodysplastic Syndromes; Thrombocytopenia |
Amgen |
2006-12 | PHASE2 |
| NCT00564889 | COMPLETED | Multiple Myeloma and Plasma Cell Neoplasm |
Mayo Clinic |
2007-12 | PHASE2 |
| NCT00474188 | TERMINATED | Diffuse Large B-cell Lymphoma |
Celgene Corporation |
2007-05 | PHASE2 |
| NCT00305812 | COMPLETED | Multiple Myeloma and Plasma Cell Neoplasm |
NCIC Clinical Trials Group |
2006-03-09 | PHASE2 |
| NCT00179660 | COMPLETED | Non-Hodgkins Lymphoma |
Celgene Corporation |
2005-08 | PHASE2 |
| NCT00477750 | COMPLETED | Multiple Myeloma and Plasma Cell Neoplasm |
Mayo Clinic |
2005-06 | PHASE1; PHASE2 |
| NCT00179673 | COMPLETED | Non-Hodgkins Lymphoma |
Celgene |
2005-06 | PHASE2 |
| NCT00109772 | TERMINATED | Complex Regional Pain Syndrome, Type I |
Celgene Corporation |
2005-02 | PHASE2 |
| NCT00961467 | COMPLETED | Multiple Myeloma |
Fondazione EMN Italy Onlus |
2007-02 | PHASE2 |
| NCT00412581 | COMPLETED | Melanoma |
M.D. Anderson Cancer Center |
2005-09 | PHASE1 |
| NCT00031941 | COMPLETED | Lymphoma; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific |
National Institutes of Health Clinical Center (CC) |
2002-04 | PHASE1 |
| NCT00046735 | COMPLETED | Neoplasms |
Celgene |
2002-06-01 | PHASE1 |
| NCT00142168 | TERMINATED | Waldenstrom's Macroglobulinemia |
Dana-Farber Cancer Institute |
2004-09 | PHASE2 |
| NCT00096525 | COMPLETED | Kidney Cancer |
Memorial Sloan Kettering Cancer Center |
2004-07 | PHASE2 |
| NCT00925821 | COMPLETED | Multiple Myeloma |
Wuerzburg University Hospital |
2009-06 | PHASE2 |
| NCT00179686 | COMPLETED | Non-Small Cell Lung Cancer |
Celgene Corporation |
2005-03 | PHASE2 |
| NCT00424229 | UNKNOWN | Myelodysplastic Syndromes |
Groupe Francophone des Myelodysplasies |
2006-10 | PHASE2 |
| NCT00833534 | WITHDRAWN | Leukemia; Lymphoma |
Fred Hutchinson Cancer Center |
2009-02 | PHASE2 |
| NCT01127542 | TERMINATED | Chronic Lymphocytic Leukaemia |
The Christie NHS Foundation Trust |
2010-05 | PHASE2 |
| NCT00179751 | TERMINATED | Pancreatic Cancer |
Celgene Corporation |
2005-04 | PHASE1; PHASE2 |
(data from https://clinicaltrials.gov, updated on 2026-06-18)
Check the
CC-5013 (Lenalidomide)
product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.
Mechanism and Biochemical Profile
Appendix RUO and cGMP Quality Standards
| Quality Dimension | RUO (Research Use Only) | cGMP (Current Good Manufacturing Practice) |
|---|---|---|
| Clinical Applicability | Prohibited in human clinical trials or medical diagnostics. | Mandatory for human clinical trials (Phase I–III) and therapies. |
| Regulatory Status | Non-regulated grade; exempt from drug manufacturing laws. | Legally enforced by health authorities (e.g., FDA, EMA, NMPA). |
| Facility Environment | Unclassified analytical or research laboratories. | Validated Cleanrooms (ISO Class 5–8) with continuous monitoring. |
| Quality Control | Basic purity and activity testing. | Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma). |
| Process Validation | Basic equipment calibration; no process validation required. | Full qualification (IQ/OQ/PQ) and complete batch records. |
| Quality Assurance | Vendor self-declared without required formal QMS. | Mandatory QA/QC unit, Change Control, CAPA, and vendor audits. |
| Regulatory Impact | High risk of IND rejection if used as a critical raw material. | Required for IND/NDA filings, supported by Drug Master Files (DMF). |
Footnotes
Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).
- CC-5013 (Lenalidomide) Mechanism of Action: CRBN Inhibition in Plasma Cells Research
- CC-5013 (Lenalidomide) Working Concentration | Cell Culture | Treatment
- CC-5013 (Lenalidomide) Solubility in DMSO
- CC-5013 (Lenalidomide) Stock Solution
- CC-5013 (Lenalidomide) Storage
- CC-5013 (Lenalidomide) Stability
- CC-5013 (Lenalidomide) Combination Database
- CC-5013 (Lenalidomide) Molecular Weight
- CC-5013 (Lenalidomide) SMILES
- CC-5013 (Lenalidomide) CAS Number
- CC-5013 (Lenalidomide) Chemical Structure (2D and 3D)
- CC-5013 (Lenalidomide) IC50 for Cell-based and Cell-free Assays
- CC-5013 (Lenalidomide) Sigma (SML2283)? Try a better option.
- CC-5013 (Lenalidomide) Cayman (14643)? Try a better option.
- CC-5013 (Lenalidomide) MedChemExpress (HY-A0003)? Try a better option.
- CC-5013 (Lenalidomide) APExBIO (A3547)? Try a better option.
- CC-5013 (Lenalidomide) SDS｜MSDS
Note: Technical data last updated: Sep 1, 2026.